Displaying 1 - 12 of 31
General Hepatology
5

LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
5

LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
5

LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
5

LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
5

LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Immune-Mediated and Cholestatic Diseases
1

Mirum Pharmaceuticals, Inc: "Meet the Experts in Cholestatic Liver Disease" - EASL Congress 2023

View
Displaying 1 - 12 of 31